List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 60 studies with search of: REVLIMID AND MYELOMA | Open Studies
Include studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Recruiting Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: lenalidomide (Revlimid®);   Drug: Cyclophosphamide;   Drug: Prednisone
2 Recruiting Lenalidomide and Dexamethasone With/Without Transplant in Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide;   Drug: Dexamethasone
3 Recruiting Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: lenalidomide
4 Recruiting Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide;   Drug: Prednisone;   Drug: Dexamethasone
5 Recruiting Dose-Finding of Lenalidomide as Maintenance in Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Revlimid (Lenalidomide)
6 Recruiting Lenalidomide, Thalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Condition: Myeloma
Interventions: Drug: Lenalidomide;   Drug: Thalidomide;   Drug: Dexamethasone
7 Recruiting Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance RX
Condition: Multiple Myeloma
Intervention: Drug: Lenalidomide
8 Recruiting Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: thalomid;   Drug: lenalidomide;   Drug: clarithromycin;   Drug: dexamethasone
9 Not yet recruiting A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Vorinostat, Lenalidomide, Bortezomib, Dexamethasone
10 Recruiting Comparison of 25mg Versus 5 mg Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Lenalidomide
11 Recruiting Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib;   Drug: dexamethasone;   Drug: lenalidomide
12 Recruiting Combination of Lenalidomide and Autologous Mature Dendritic Cells Pulsed With KRN7000 in Myeloma
Condition: Myeloma
Interventions: Drug: Lenalidomide;   Biological: Monocyte derived DCs loaded with KRN7000
13 Recruiting Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Lenalidomide, Bendamustine, Prednisone
14 Recruiting Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: lenalidomide;   Drug: melphalan;   Drug: prednisone;   Drug: thalidomide
15 Recruiting Lenalidomide-Adriamycin-Dexamethasone (RAD) Induction Followed by Stem Cell Transplant in Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Procedure: allogeneic stem cell transplant versus second autologous transplantation;   Drug: RAD
16 Recruiting Lenalidomide (Revlimid) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance Ld for SCT Patients Not Achieving at Least Very Good Partial Response (VGPR) or Having High-risk Disease
Condition: Multiple Myeloma
Interventions: Procedure: Stem cell transplant x 1 or x 2;   Drug: lenalidomide and dexamethasone
17 Recruiting Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib;   Drug: dexamethasone;   Drug: lenalidomide
18 Recruiting Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide (Revlimid);   Drug: Melphalan;   Drug: Dexamethasone
19 Recruiting Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide and low-dose dexamethasone;   Drug: Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles;   Drug: Melphalan, Prednisone and Thalidomide
20 Recruiting Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: dexamethasone;   Drug: lenalidomide;   Other: flow cytometry;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Other: staining method;   Procedure: bone marrow aspiration

Previous Page Studies Shown (1-20) Next Page (21-40)
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
RSS Feeds for studies found by your search that were:
  First received in the last 14 days,  
  Last updated (includes received) in the last 30 days
  Download Options




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services